10X Genomics Inc (TXG)

Currency in USD
56.09
-2.06(-3.54%)
Closed·
56.81+0.72(+1.28%)
·
TXG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
55.8058.15
52 wk Range
11.1660.69
Key Statistics
Prev. Close
58.15
Open
57.15
Day's Range
55.8-58.15
52 wk Range
11.16-60.69
Volume
2.01M
Average Volume (3m)
3.26M
1-Year Change
319.8353%
Book Value / Share
6.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TXG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.54
Downside
-11.68%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

10X Genomics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

6 Buy
10 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 49.54
(-11.68% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stephens
Buy65.00+15.89%50.00MaintainAug 12, 2026
Piper Sandler
Hold47.00-16.21%42.00MaintainAug 10, 2026
Canaccord
Buy60.00+6.97%50.00MaintainAug 10, 2026
Stifel
Buy50.00-10.86%25.00MaintainAug 07, 2026
Citi
Hold45.00-19.77%-New CoverageJul 30, 2026

10X Genomics Inc SWOT Analysis


Genomic Frontiers
Explore 10X Genomics' innovative fusion of technologies, positioning the company at the forefront of single-cell and spatial genomics advancements
Financial Headwinds
Delve into TXG's financial challenges, including negative EPS forecasts and potential NIH funding cuts, impacting 20% of indirect business
Market Dynamics
Uncover TXG's strategic moves to expand its customer base with more affordable solutions, navigating a competitive genomics technology landscape
Future Trajectory
Analyst targets range from $13 to $17, with Barclays maintaining an Overweight rating at $15, reflecting cautious optimism amid funding uncertainties
Read full SWOT analysis

10X Genomics Inc Earnings Call Summary for Q2/2026

  • 10x Genomics Q2 revenue rose 3% YoY to $151M, beating estimates; adjusted loss of $0.14/share topped forecast of $0.24 loss; shares fell 6.8% after-hours.
  • Consumables revenue grew 7% YoY with spatial up 16%; instrument sales dropped 47% as customers await new Atera platform launch.
  • Company raised FY2026 revenue guidance to $610M-$630M but expects Q3 sequential decline before Q4 recovery driven by Atera shipments.
  • Strong Atera demand exceeds shipment capacity; ~40 units expected in H2 2026, mostly Q4, with manufacturing constraints limiting near-term growth.
  • Gross margin improved to 74% from 72% YoY; cash position strengthened to $552M, up $105M year-over-year despite ongoing losses.
Last Updated: 08/07/2026, 07:14 AM
Read Full Transcript

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-0.14 / -0.24
Revenue / Forecast
151.04M / 146.64M
EPS Revisions
Last 90 days

TXG Income Statement

Compare TXG to Peers and Sector

Metrics to compare
TXG
Peers
Sector
Relationship
P/E Ratio
−97.3x−7.9x−0.4x
PEG Ratio
−6.51−0.090.00
Price/Book
8.9x2.2x2.6x
Price / LTM Sales
11.8x4.1x3.1x
Upside (Analyst Target)
−10.9%28.1%47.9%
Fair Value Upside
Unlock7.1%6.3%Unlock

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
69.69M54.89%3.91B
Other Institutional Investors
53.11M41.83%2.98B
Public Companies & Retail Investors
4.16M3.27%233.14M
Total
126.96M100.00%7.12B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC14.30%18,633,1981,045,136
ARK Investment Management LLC8.99%11,717,317657,224

People Also Watch

52.10
TEM
-4.03%
140.00
SPCX
-0.91%
26.75
BEAM
+0.91%
13.580
RDW
+2.88%

FAQ

What Is the 10X Genomics (TXG) Stock Price Today?

The 10X Genomics stock price today is 56.09 USD.

What Stock Exchange Does 10X Genomics Trade On?

10X Genomics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for 10X Genomics?

The stock symbol for 10X Genomics is "TXG."

What Is the 10X Genomics Market Cap?

As of today, 10X Genomics market cap is 7.31B USD.

What Is 10X Genomics's Earnings Per Share (TTM)?

The 10X Genomics EPS (TTM) is -0.59.

When Is the Next 10X Genomics Earnings Date?

10X Genomics will release its next earnings report on Nov 04, 2026.

From a Technical Analysis Perspective, Is TXG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has 10X Genomics Stock Split?

10X Genomics has split 0 times.

How Many Employees Does 10X Genomics Have?

10X Genomics has 1178 employees.

What is the current trading status of 10X Genomics (TXG)?

As of Aug 17, 2026, 10X Genomics (TXG) is trading at a price of 56.09 USD, with a previous close of 58.15 USD. The stock has fluctuated within a day range of 55.80 USD to 58.15 USD, while its 52-week range spans from 11.16 USD to 60.69 USD.

What Is 10X Genomics (TXG) Price Target According to Analysts?

The average 12-month price target for 10X Genomics is 49.54 USD, with a high estimate of 65 USD and a low estimate of 40 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -11.68% Downside potential.

What Is the TXG Premarket Price?

TXG's last pre-market stock price is 57.07 USD. The pre-market share volume is 2,170.00, and the stock has decreased by -1.08, or -1.86%.

What Is the TXG After Hours Price?

TXG's last after hours stock price is 56.81 USD, the stock has decreased by 0.72, or 1.28%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.